ArticleSmart medicine2023
Organ-on-a-chip technologies for biomedical research and drug development: A focus on the vasculature.
Article in Smart medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Engineering Multiscale Vasculature: Biological Principles, Design Constraints, and Advanced Biofabrication Strategies for Functional Vascular Networks.Biomimetics (Basel, Switzerland) · 2026Review
- A Machine Vision-Guided Microphysiological Platform With Automated Microfluidics Enables Longitudinal Biomarker Monitoring and Emulation of Translationally Relevant Exposure Scenarios.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Development of a Synthetic Hydrogel to Foster Microvascularization of an Endometriosis Microphysiological System.Advanced healthcare materials · 2026Article
- Innovative micro physiological systems for vaccine development.Human vaccines & immunotherapeutics · 2025Review
- Advancements and Future Perspectives of Microfluidic Technology in Pediatric Healthcare.Smart medicine · 2025Review
- Integrating melt electrospinning writing and microfluidics to engineer a human cardiac microenvironment for high-fidelity drug screening.Bioactive materials · 2025Article
- Bridging the gap: From petri dish to patient - Advancements in translational drug discovery.Heliyon · 2025Review
- Endothelial Dysfunction in Atherosclerosis: Experimental Models and Therapeutics.Biomaterials research · 2025Review
- In Vitro Modeling of Vascular Senescence.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Progress in the Application of Organoids-On-A-Chip in Diseases.Organogenesis · 2024Review
- FromLab on a chip · 2024Article
- Tissue-Penetrating Ultrasound-Triggered Hydrogel for Promoting Microvascular Network Reconstruction.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Developing organs-on-chips for biomedical applications.Smart medicine · 2024Review
- Microfluidic printed 3D bioactive scaffolds for postoperative treatment of gastric cancer.Materials today. Bio · 2024Article
- Modeling, applications and challenges of inner ear organoid.Smart medicine · 2024Review
- A method to generate perfusable physiologic-like vascular channels within a liver-on-chip model.Biomicrofluidics · 2023Article
- Organ-on-a-chip technologies for biomedical research and drug development: A focus on the vasculature.Smart medicine · 2023Article
- Recent advances in liver-on-chips: Design, fabrication, and applications.Smart medicine · 2023Review
- Tissue adhesives for wound closure.Smart medicine · 2023Article
- Emerging technologies for cardiac tissue engineering and artificial hearts.Smart medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Current biomedical models fail to replicate the complexity of human biology. Consequently, almost 90% of drug candidates fail during clinical trials after decades of research and billions of investments in drug development. Despite their physiological similarities, animal models often misrepresent human responses, and instead, trigger ethical and societal debates regarding their use. The overall aim across regulatory entities worldwide is to replace, reduce, and refine the use of animal experimentation, a concept known as the Three Rs principle. In response, researchers develop experimental alternatives to improve the biological relevance of in vitro models through interdisciplinary approaches. This article highlights the emerging organ-on-a-chip technologies, also known as microphysiological systems, with a focus on models of the vasculature. The cardiovascular system transports all necessary substances, including drugs, throughout the body while in charge of thermal regulation and communication between other organ systems. In addition, we discuss the benefits, limitations, and challenges in the widespread use of new biomedical models. Coupled with patient-derived induced pluripotent stem cells, organ-on-a-chip technologies are the future of drug discovery, development, and personalized medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.